Literature DB >> 11153447

Sensitivity analysis of pharmacokinetic and pharmacodynamic systems: I. A structural approach to sensitivity analysis of physiologically based pharmacokinetic models.

I A Nestorov1.   

Abstract

Based on a frequency response approach to the sensitivity analysis of pharmacokinetic models, the concept of structural sensitivity is introduced. The core of this concept is the factorization of the system sensitivity into two multipliers. The first one, called structural sensitivity index, has an analytical form, which depends solely on the structure and connectivity of the system and does not depend on the drug administered or the factor perturbed. The second multiplier, the parameter sensitivity index, depends on the drug properties, the tissue of interest and the parameter perturbed, but is largely independent of the structure of the system. The structural and parametric sensitivity indices can be evaluated and analyzed separately. The most important feature of the proposed approach is that the conclusions drawn from the analysis of the structural sensitivity index are valid across all mammalian species, as the latter share a common anatomical and physiological structure. The concept of structural sensitivity is illustrated on the commonly used structure of the whole body physiologically based pharmacokinetic models by showing that the factorization of the sensitivity carried out arises naturally from the mechanism of the distribution of perturbations throughout the organism. The concept of structural sensitivity has interesting practical implications. It enables the formal proof of relationships and facts that have been observed previously. Moreover, the conclusions drawn introduce in fact a ranking of the tissues or subsystems with respect to their impact on the model outputs. From this ranking, direct recommendations regarding the design of experiments for whole-body physiologically based pharmacokinetic models are derived.

Entities:  

Mesh:

Year:  1999        PMID: 11153447     DOI: 10.1023/a:1020926525495

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  15 in total

1.  Sensitivity analysis for physiologically based pharmacokinetic models.

Authors:  D M Hetrick; A M Jarabek; C C Travis
Journal:  J Pharmacokinet Biopharm       Date:  1991-02

2.  Modeling benzene pharmacokinetics across three sets of animal data: parametric sensitivity and risk implications.

Authors:  R C Spear; F Y Bois; T Woodruff; D Auslander; J Parker; S Selvin
Journal:  Risk Anal       Date:  1991-12       Impact factor: 4.000

3.  Frequency response method in pharmacokinetics.

Authors:  L Dedík; M Durisová
Journal:  J Pharmacokinet Biopharm       Date:  1994-08

4.  Lumping of whole-body physiologically based pharmacokinetic models.

Authors:  I A Nestorov; L J Aarons; P A Arundel; M Rowland
Journal:  J Pharmacokinet Biopharm       Date:  1998-02

5.  Pharmacokinetics from a dynamical systems point of view.

Authors:  J M van Rossum; J E de Bie; G van Lingen; H W Teeuwen
Journal:  J Pharmacokinet Biopharm       Date:  1989-06

6.  An extended physiological pharmacokinetic model of methadone disposition in the rat: validation and sensitivity analysis.

Authors:  J L Gabrielsson; T Groth
Journal:  J Pharmacokinet Biopharm       Date:  1988-04

7.  Effect of parameter variability on physiologically-based pharmacokinetic model predicted drug concentrations.

Authors:  P Varkonyi; J V Bruckner; J M Gallo
Journal:  J Pharm Sci       Date:  1995-03       Impact factor: 3.534

8.  Uncertainty, variability, and sensitivity analysis in physiological pharmacokinetic models.

Authors:  D Krewski; Y Wang; S Bartlett; K Krishnan
Journal:  J Biopharm Stat       Date:  1995-11       Impact factor: 1.051

9.  The importance of anatomical realism for validation of physiological models of disposition of inhaled toxicants.

Authors:  M C Kohn
Journal:  Toxicol Appl Pharmacol       Date:  1997-12       Impact factor: 4.219

10.  Physiologic modeling of cyclosporin kinetics in rat and man.

Authors:  A Bernareggi; M Rowland
Journal:  J Pharmacokinet Biopharm       Date:  1991-02
View more
  13 in total

1.  In silico prediction of optimal in vivo delivery properties using convolution-based model and clinical trial simulation.

Authors:  Roberto Gomeni; Carla Dangeli; Alan Bye
Journal:  Pharm Res       Date:  2002-01       Impact factor: 4.200

Review 2.  Whole body pharmacokinetic models.

Authors:  Ivan Nestorov
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 3.  Biomarkers, validation and pharmacokinetic-pharmacodynamic modelling.

Authors:  Wayne A Colburn; Jean W Lee
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

4.  Physiologically based pharmacokinetic model for composite nanodevices: effect of charge and size on in vivo disposition.

Authors:  Donald E Mager; Vidhi Mody; Chao Xu; Alan Forrest; Wojciech G Lesniak; Shraddha S Nigavekar; Muhammed T Kariapper; Leah Minc; Mohamed K Khan; Lajos P Balogh
Journal:  Pharm Res       Date:  2012-06-12       Impact factor: 4.200

5.  Partial derivative-based sensitivity analysis of models describing target-mediated drug disposition.

Authors:  Anson K Abraham; Wojciech Krzyzanski; Donald E Mager
Journal:  AAPS J       Date:  2007-06-08       Impact factor: 4.009

Review 6.  Design Automation in Synthetic Biology.

Authors:  Evan Appleton; Curtis Madsen; Nicholas Roehner; Douglas Densmore
Journal:  Cold Spring Harb Perspect Biol       Date:  2017-04-03       Impact factor: 10.005

7.  Use of a local sensitivity analysis to inform study design based on a mechanistic toxicokinetic model for γ-hydroxybutyric acid.

Authors:  Melanie A Felmlee; Wojciech Krzyzanski; Bridget L Morse; Marilyn E Morris
Journal:  AAPS J       Date:  2011-03-09       Impact factor: 4.009

8.  Comparison of two pharmacodynamic transduction models for the analysis of tumor therapeutic responses in model systems.

Authors:  Jun Yang; Donald E Mager; Robert M Straubinger
Journal:  AAPS J       Date:  2009-11-10       Impact factor: 4.009

9.  Population PK-PD model for Fc-osteoprotegerin in healthy postmenopausal women.

Authors:  Matthew L Zierhut; Marc R Gastonguay; Steven W Martin; Paolo Vicini; Pirow J Bekker; Donna Holloway; Philip T Leese; Mark C Peterson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-07-17       Impact factor: 2.745

10.  The implications of using a physiologically based pharmacokinetic (PBPK) model for pesticide risk assessment.

Authors:  Chensheng Lu; Christina M Holbrook; Leo M Andres
Journal:  Environ Health Perspect       Date:  2010-01       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.